Fate Therapeutics, Inc. · NASDAQ:FATE
Fate Therapeutics — Investor Presentation (August 2026)
36 slides from Fate Therapeutics's investor presentation, August 2026
Slide 1: Transforming the Lives of Patients Living with Autoimmune Diseases and Cancer
TRANSFORMING THE LIVES OF PATIENTS LIVING WITH AUTOIMMUNE DISEASES AND CANCER Making Cell Therapies Accessible to All TM CORPORATE PRESENTATION August 2026 | NASDAQ: FATE 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety and therapeutic potential of the Company’s product candidates, the advancement of and plans and tim
Slide 3: Making the Transformative Value of Cell Therapy Accessible to All
Making the Transformative Value of Cell Therapy Accessible to All Best-in-Class Single Cell Engineering Platform Recognized as the pioneer in creating clonal iPSC master cell banks Industrialized Scale, Off-the-Shelf CAR T cells for Broad Patient Access Unique manufacture platform enables broad pati
Slide 4: Platform Enables Unparalleled Cell Manufacturing Capability
Platform Enables Unparalleled Cell Manufacturing Capability Induced Single product Clonal master Stored drug Treat thousands of pluripotent candidate clone cell bank (MCB) inventory patients on-demand stem cell (iPSC) MCB vial acts as Clonal sorting iPSC expansion manufacturing Single step and selec
Slide 5: Transformative Off-the-Shelf Cell Therapy Product Pipeline
Transformative Off-the-Shelf Cell Therapy Product Pipeline Development of cellular medicines for complex diseases Phase 2/ Asset Name CAR Target/Product Profile Indication Pre Clinical Phase 1 Partner Registrational Autoimmunity Lupus Nephritis (LN) (RMAT) FT819-201 (RECLAIM-LN) NCT07570862 FT819 CD
Slide 6: Delivering Unparalleled Value & Access to Patients
Delivering Unparalleled Value & Access to Patients Conventional Autologous CAR T-cell Therapy Not available on-demand Versus Total Therapy time > 6 weeks OUTPATIENT-ENABLED TREATMENT PARADIGM FOR CAR T-CELL THERAPY • Off-the-shelf and on demand delivery model enables accelerated and patient friendly
Slide 7: FT819 RECLAIM-LN Trial: Phase 2 Potentially Registrational Trial in Lupus Nephritis
FT819 RECLAIM-LN Trial Phase 2 Potentially Registrational Trial in Lupus Nephritis Making Cell Therapy Accessible to All 7
Slide 8: FT819: Anti-CD19 CAR T-Cell Product Candidate
FT819: Anti-CD19 CAR T-Cell Product Candidate Safe and effective targeting of CD19+ B cells with broad patient accessibility Off-the-Shelf CD19 CAR T-cell derived from a Engineered Attribute Systems defined clonal MCB incorporating designed functional elements to balance safety & efficacy1 • 1XX CD1
Slide 9: Lupus Nephritis: High Burden, High Unmet Need
Lupus Nephritis: High Burden, High Unmet Need Systemic lupus erythematosus (SLE) Patient & Therapeutic Opportunity ~200-400K US patients1-2 Current approved standard of care (SoC) therapies leave ~60-75% of patients without a complete renal Lupus nephritis (LN) ~40% of total SLE3 response (CRR) ~160
Slide 10: Planned Pivotal Phase 2 Trial to Accelerate CAR T-cell Therapy in LN
Planned Pivotal Phase 2 Trial to Accelerate CAR T-cell Therapy in LN RECLAIM-LN Trial Open label, Single arm Phase 2 potentially registrational study for patients with refractory moderate-to- severe SLE with lupus nephritis (LN)1,2 LTFU = Long-term follow-up; PTFU = Post-treatment follow-up. KEY PAR
Slide 11: RECLAIM-LN Trial Status
RECLAIM-LN Trial Status Enrollment Open First 5 Sites Active US + UK + BRAZIL First patient treated and multiple Goal to reach 20 sites by YE 2026 Planned geographic footprint patients in pre-screening / screening as of Aug 12th 2H 2026 2H 2027 1H 2028 1 2 3 Commenced enrollment Planned Interim anal
Slide 12: FT839 COMPLETE Trial: Phase 1/2 Basket Trial in Autoimmune Disease
FT839 COMPLETE Trial Phase 1/2 Basket Trial in Autoimmune Disease Making Cell Therapy Accessible to All 12
Slide 13: Next-Generation CD19/CD38 Dual CAR T cell for Comprehensive Disease Elimination
Next-Generation CD19/CD38 Dual CAR T cell Broadly Targeting Aberrant Immune Cells for a Comprehensive Approach to Disease Elimination Engineered Attribute Systems Transformative 13-point edited off-the-shelf CAR T cell built for comprehensive elimination • CD19 CAR + CD38 CAR: Unique dual CAR design
Slide 14: CD19 and CD38 Co-Targeting by FT839 Eliminates Activated and Proliferating Cells
CD19 and CD38 co-Targeting by FT839 Selectively Eliminate Activated and Proliferating Cells Across Various Immune Cell Subsets Antigen surface expression per immune cell subset1 CD19 Expression CD38 Expression Unlike CD19 targeting alone, FT839 with dual CD19 and CD38 targeting provides comprehensiv
Slide 15: FT839 Multi-Indication Capacity Supports a 'Pipeline-in-a-Product'
FT839 Multi-Indication Capacity Supports a ‘Pipeline-in-a-Product’ Significant market opportunity across autoimmunity, inflammation and oncology Extent of FT839 application AU T O IMMU NE D IS EAS E S H EM A T O LO G IC A L M A LIG NA NC IES across autoimmune diseases (AD), broader immunology/inflam
Slide 16: Phase 1/2 Basket Trial of FT839 in Autoimmune Disease
Phase 1/2 Basket Trial of FT839 in Autoimmune Disease Facilitates Accelerated Clinical Development COMPLETE Trial Phase 1/2 trial design to enable accelerated development across multiple indications with seamless transition from dose-escalation, dose-expansion to Phase 2 cohorts (formerly FT839-101)
Slide 17: FT819-102 Trial Summary: Phase 1 Basket Trial in Autoimmune Disease
FT819-102 Trial Summary Phase 1 Basket Trial in Autoimmune Disease Making Cell Therapy Accessible to All 17
Slide 18: FT819 Ph1 Takeaways Support Ph2 RECLAIM Trial in Lupus and Scleroderma
FT819 Ph1 Takeaways Support Ph2 RECLAIM Trial in Lupus and Future Opportunities in Scleroderma Favorable Safety Profile & Manufacturing Reliability Unlock Broad Patient Access • Differentiated CD19 CAR design and less-intensive conditioning supported a positive patient experience, accelerated enroll
Slide 19: FT819 Demonstrates Rapid & Sustained Clinical Improvement with Favorable Safety
FT819 Demonstrates Rapid & Sustained Clinical Improvement with Favorable Safety Response1-2 UPCr cSLEDAI-2K Score 4 16 3 Safety Parameter Incidence, n (%) (N=16) 3 12 cSLEDAI-2K Score CRS (Grades 1-2) 4 (25.0) 2 UPCr (mg/mg) PGA Score 2 8 CRS (Grade ≥3) 0 1 1 4 0.5 mg/mg* ICANS 0 0 0 0 GvHD 0 BL1 2
Slide 20: FT819 Drives Deep B Cell Depletion and Compartment Remodeling
400 Absolute cell (cells/u 200 200 150 FT819 Drives Deep B Cell Depletion and Compartment Remodeling 100 50 0 LLOQ 1M 3M 6M 12M 18M 24M BL Peripheral and tissue B cell depletion and clonal BCR repertoire remodeling post bendamustine & FT819 treatment Bendamustine (N=7) 2.0 1000 (n=7) Peripheral bloo
Slide 21: Clinical Activity Without Conditioning Chemotherapy in SLE
Preliminary Clinical Data Highlights FT819 Activity and Clinical Benefit Without the Use of Conditioning Chemotherapy in SLE B cell depletion and improved SLEDAI scores following single low-dose (360M) treatment of FT819 without conditioning chemotherapy (CCT)1 SLEDAI FACIT Fatigue SLEDAI-2K Score 1
Slide 22: Preliminary FT819 Safety & Clinical Activity in Systemic Sclerosis
Preliminary FT819 Safety & Clinical Activity in Patients with Systemic Sclerosis Dose of 900M cells shows favorable safety profile and significant clinical impact1 Participant Inclusion Criteria • All participants must meet ACR/EULAR 2013 SSc criteria • Tried and failed, or intolerant to, ≥ 2 immuno
Slide 23: FT836-101 PANACEA Trial: Phase 1 Basket Trial in Solid Tumors
FT836-101 PANACEA Trial Phase 1 Basket Trial in Solid Tumors Making Cell Therapy Accessible to All 23
Slide 24: Next-Generation CAR T cell Targeting MICA/B
Next-Generation CAR T cell Targeting MICA/B Designed to Eliminate a Broad Spectrum of Tumors Engineered Attribute Systems Novel stress-antigen targeting off-the-shelf CAR T cell built to overcome cancer’s ability • MICA/B CAR: A novel CAR design that uniquely targets stress ligands MICA/B to escape
Slide 25: Targeting MICA/B Overcomes Tumor Evasion for Pan-Tumor Opportunity
Targeting MICA/B in a Novel Manner Overcomes Tumor Evasion to Unlock Pan-Tumor Treatment Opportunity in Multiple Cancers Novel recognition of MICA/B α3 domain unlocks MICA/B is widely expressed pan-tumor recognition1,2 across ~98% of all cancer indications5 MICB RNA Expression Overcoming cancer’s im
Slide 26: Panacea Clinical Trial: Targeting Solid Tumors with CAR T cells
Panacea Clinical Trial: Targeting Solid Tumors with CAR T cells Equipped with Novel Pan-Tumor Recognition Highly-Differentiated PANACEA Trial (FT836-101): Phase 1 Solid Tumor Therapeutic Approach1 Basket Study ➢ Requires no patient apheresis and provides an option for no conditioning chemotherapy Ph
Slide 27: Preliminary Anti-Tumor Activity Observed in Colorectal Cancer Patients
Preliminary Anti-Tumor Activity Observed in Colorectal Cancer Patient Subset without Conditioning Chemotherapy in the Panacea Trial CLINICAL CASE 11,2 CLINICAL CASE 2 1,2 • 45/M with metastatic CRC, KRAS wild-type (KRASWT) • 53/M with metastatic CRC, KRASWT • 7 prior lines of therapy, including cetu
Slide 28: Tumor Tissue Trafficking and Functional Persistence Without Conditioning Chemotherapy
Preliminary Clinical Data Demonstrates Tumor Tissue Trafficking and Functional Persistence without the Need for Conditioning Chemotherapy Increased CD8 T cell numbers detected in FT836 persistence in blood and tumor tissue post infusion tumor tissue post infusion Red box highlights Orange arrows hig
Slide 29: Partnerships & CAR NK Cell Program
Partnerships & CAR NK Cell Program Making Cell Therapy Accessible to All 29
Slide 30: Pipeline Breadth Holds Significant Value Across Oncology & Autoimmune Disease
Pipeline Breadth Holds Significant Value Across Oncology & Autoimmune Disease Multi-Antigen Targeting CD19 CAR NK Cell FT825/ONO-8250: ADR enabled to reduce/eliminate the need for Off-the-shelf anti-HER2 CAR T-cell product candidate with conditioning chemotherapy trafficking and tumor microenvironme
Slide 31: Regenerative Medicine Programs
Regenerative Medicine Programs Making Cell Therapy Accessible to All 31
Slide 32: Comprehensive Approach to Cell Therapy and Regenerative Medicine
Comprehensive Approach to Cell Therapy and Regenerative Medicine Regenerative Medicine Preclinical Programs Protected by ALLO-360TM Technology • One iPSC platform, multiple therapeutic opportunities1-4 • Allo-immune engineered to prevent patient-derived immune recognition and elimination • Combining
Slide 33: Finance & Business Updates
Finance & Business Updates Making Cell Therapy Accessible to All 33
Slide 34: Q2 2026 Financial Snapshot
Q2 2026 Financial Snapshot Strong balance sheet and financial discipline CASH & SHORT-TERM CASH RUNWAY WEIGHTED-AVG SHARES INVESTMENTS OUTSTANDING $153.8M Into 2028 120.2M (Manufacturing Cost Already Incurred) (Six Months Ended June 30th, 2026) EXPENSE BREAKDOWN ($ THOUSANDS) TOTAL H1 2026 VS. H1 20
Slide 35: Near-Term Value-Driving Milestones
Near-Term Value-Driving Milestones Autoimmune Development FT819: Accelerate RECLAIM-LN patient enrollment & clinical site activation Evaluate readiness for ERL-LN and SSc pivotal trial design and execution Continue generating no-conditioning & multi-dosing regimen datasets FT839: Advance the commenc
Slide 36: Thank You
Thank You Making Cell Therapy Accessible to All 36
Fate Therapeutics — Investor Presentation (August 2026) on 6ix